Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...

Merck is discussing the study data with regulators worldwide, with a goal of making the treatment available for infants as early as the 2025 to 2026 RSV season.

Study explores the clinical manifestations, risk factors, and 90-day mortality outcomes in adults hospitalized with RSV or ...

Despite being back in the season of sniffles and sick days, Washington state will be extra equipped to battle the spread of respiratory viruses this year.

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

NanoViricides, Inc. (NYSE Amer.: NNVC ) (the “Company”), a clinical stage global leader in broad-spectrum antiviral ...

Dr Xand van Tulleken has addressed public confusion surrounding different types of vaccination, amid fears of a "tripledemic" ...

Detailed data from a Phase 2b/3 study of Merck’s treatment clesrovimab should support the company’s efforts to win approval ...

The protection also held across different strains, for people in their 70s, and for those with underlying medical conditions.

Expanded access to addiction treatment and the overdose-reversal med naloxone likely prompted a 37% reduction in OD deaths ...

The Eastern Ontario Health Unit is advising a new treatment is now available in the region to help protect infants from the most-severe effects of respiratory syncytial virus (RSV).